HDL cholesterol (HDL-C) is a lipoprotein that transports cholesterol from tissues back to the liver for disposal. Despite decades of "good cholesterol" framing, recent Mendelian randomization and large pharmacological trials show that genetically or pharmacologically raised HDL does not reduce cardiovascular events. HDL remains a useful biomarker because it tracks metabolic health — particularly insulin sensitivity, physical activity, and triglyceride metabolism — but it is not an intervention target itself. ApoB (apolipoprotein B), which measures total atherogenic particle count, is the primary predictor of cardiovascular risk.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you have cardiovascular risk factors — family history of heart disease, high blood pressure, metabolic syndrome, or elevated triglycerides — testing HDL gives you one piece of your lipid picture. HDL levels often reflect broader metabolic health: high physical activity, good insulin sensitivity, and healthy triglyceride levels tend to cluster with higher HDL. Testing it matters because low HDL can flag a pattern of metabolic dysfunction that deserves attention, even if other markers look normal.
However, HDL alone is not sufficient to assess cardiovascular risk. Your ApoB count and LDL particle number matter far more for predicting heart disease. Standard Swedish healthcare tests HDL automatically as part of a lipid panel, but understanding what it actually predicts — and what it doesn't — is critical to avoiding false reassurance or unnecessary worry.
Flags metabolic dysfunction. Low HDL often appears alongside insulin resistance, obesity, and elevated triglycerides, signaling a need for deeper metabolic evaluation even when LDL or other markers look acceptable.
Tracks response to lifestyle intervention. HDL responds reliably to physical activity, weight loss, and reduced refined carbohydrate intake, making it a useful proxy for metabolic fitness.
Contextualizes lipid patterns. HDL helps interpret the LDL-HDL ratio and triglyceride-to-HDL ratio, which are stronger predictors of small, dense LDL particles than LDL cholesterol alone.
Guides preventive medicine decisions. Low HDL combined with other risk factors (elevated ApoB, hs-CRP, poor glycemic control) increases urgency for comprehensive risk assessment and lifestyle optimization.
Supports cardiology consultation. When HDL is very low (< 0.9 mmol/L) alongside other abnormalities, it strengthens the case for specialist evaluation and risk stratification.
Monitors long-term metabolic health. Annual HDL tracking reveals whether your exercise, nutrition, and stress management are maintaining metabolic resilience.
The structural role: ApoA1 and reverse cholesterol transport. HDL particles are built around apolipoprotein A1 (ApoA1), a scaffolding protein that allows HDL to bind cholesterol and carry it backward — from artery walls, liver, and other tissues toward the liver for excretion via bile. This "reverse cholesterol transport" is HDL's main job. It's a real and important function, which is why HDL was historically called "protective." But protection, it turns out, requires more than HDL alone.
Why "good cholesterol" framing broke down. In the 1990s and 2000s, observational studies showed that people with higher HDL had fewer heart attacks. From this, the logic seemed straightforward: raise HDL, prevent disease. But observational data conflates correlation with causation. The people with naturally high HDL also exercised more, weighed less, had lower triglycerides, better insulin sensitivity, and lower ApoB. When genetic studies (Mendelian randomization, 2012 Voight et al. Lancet) and pharmacological trials (CETP inhibitor trials like ACCELERATE) tested whether raising HDL *itself* prevented disease, the answer was no. The protection came from the metabolic health *cluster*, not from HDL elevation in isolation.
What HDL actually predicts. HDL remains predictive of cardiovascular outcomes, but as a *proxy marker* for metabolic health rather than a causal target. Low HDL (< 1.0 mmol/L) is associated with insulin resistance, elevated triglycerides, small dense LDL particles, and systemic inflammation — the real drivers of atherosclerosis. High HDL (> 1.5 mmol/L) usually reflects good metabolic fitness. But very high HDL (> 2.5 mmol/L) has shown paradoxical associations with increased mortality in some cohorts, likely reflecting reverse causality (advanced liver disease, genetic mutations in HDL metabolism, or extreme metabolic states). The relationship is J-shaped, not linear.
Identifies metabolic clustering. Low HDL rarely travels alone — it typically clusters with elevated triglycerides, high fasting glucose, poor insulin sensitivity, and elevated ApoB. Spotting this pattern early allows intervention before overt metabolic disease emerges.
Contextualizes LDL discordance. Some people have normal LDL cholesterol but low HDL and high triglycerides. This pattern often reflects small, dense LDL particles and higher true cardiovascular risk than standard lipid reports suggest. Pairing HDL with ApoB measurement clarifies this discordance.
Tracks physical fitness and metabolic resilience. HDL responds robustly to aerobic training, strength work, and weight loss — making it a useful biomarker for whether your lifestyle interventions are working, independent of disease risk.
Guides intensity of further evaluation. Very low HDL (< 0.8 mmol/L) with elevated triglycerides or ApoB warrants more aggressive risk assessment and metabolic investigation than isolated normal ranges alone would suggest.
Standard Swedish reference (vårdcentralen): Men > 1.0 mmol/L; Women > 1.2 mmol/L. These are the minimum thresholds used in routine screening.
Loovi optimal (longevity): Men ≥ 1.3 mmol/L; Women ≥ 1.5 mmol/L. This range reflects populations with low cardiovascular event rates and better metabolic fitness.
Aggressive (individuals with high genetic risk, family history of early ASCVD, or established disease): Men ≥ 1.5 mmol/L; Women ≥ 1.7 mmol/L.
The jump from standard to optimal ranges reflects the data on physical activity and metabolic health. Higher HDL (> 1.3 mmol/L in men) is associated with lower all-cause mortality, but the benefit plateaus around 1.8–2.0 mmol/L. Values > 2.5 mmol/L, while rare, sometimes reflect genetic variants or liver disease and warrant investigation rather than celebration.
Low HDL (< 1.0 mmol/L in men, < 1.2 mmol/L in women). Low HDL typically signals metabolic dysfunction—insulin resistance, elevated triglycerides, obesity, or sedentary behavior. It often clusters with abnormal glucose control, high blood pressure, and elevated ApoB (small, dense LDL particles). This pattern, sometimes called metabolic syndrome, is associated with accelerated atherosclerosis and higher cardiovascular event risk. Low HDL also appears in chronic inflammation, chronic kidney disease, and some genetic lipid disorders. If your HDL is low, it's worth checking your fasting glucose, insulin levels, triglycerides, and ApoB to understand the full picture.
Optimal HDL (1.3–1.8 mmol/L in men, 1.5–2.0 mmol/L in women). Optimal HDL reflects good metabolic health — likely driven by regular physical activity, healthy weight, good insulin sensitivity, and favorable triglyceride levels. This range is associated with lower long-term cardiovascular risk and all-cause mortality. People in this range typically also have lower ApoB, better glycemic control, and lower systemic inflammation markers (hs-CRP). It's a sign that your lifestyle interventions are working.
High HDL (1.8–2.5 mmol/L). High HDL remains associated with low cardiovascular risk in most cohorts and often reflects elite athletic training, excellent weight management, or high-dose niacin therapy. However, values in this range don't confer extra protection beyond about 1.8–2.0 mmol/L. Most people who achieve this level do so through consistent exercise and metabolic optimization, which protects them for many reasons beyond HDL itself.
Very high HDL (> 2.5 mmol/L). Paradoxically, very high HDL has shown associations with increased mortality in some studies, though this is rare. It can reflect genetic variants in HDL metabolism (such as CETP deficiency), advanced liver disease, or other chronic conditions. If your HDL exceeds 2.5 mmol/L, it's worth discussing with your doctor to rule out underlying causes rather than assuming it's purely protective.
Factors that influence HDL levels. HDL is sensitive to physical activity (aerobic training and strength work raise it within weeks to months), alcohol consumption (moderate intake raises it; heavy drinking lowers it), body weight and composition (weight loss raises HDL), dietary carbohydrate quality (refined carbs lower it; whole grains and fiber support it), triglyceride levels (high triglycerides suppress HDL), and menstrual cycle phase in women (HDL fluctuates slightly across the cycle). Certain medications (statins, beta-blockers, some antiretrovirals) can lower HDL. Pregnancy and hormonal contraceptives can raise it. Acute illness or inflammation can transiently suppress it.
Insulin resistance and metabolic dysfunction. Hyperinsulinemia drives hepatic VLDL overproduction and suppresses ApoA1 synthesis, lowering HDL. Insulin-resistant individuals almost always have low HDL paired with elevated triglycerides. This is one of the strongest drivers of abnormal HDL.
Sedentary behavior and poor aerobic fitness. Physical activity — particularly aerobic training — is one of the most potent HDL-raising interventions. Conversely, sedentary populations consistently show low HDL. This reflects the tight coupling between physical fitness and metabolic health.
Elevated triglycerides and small, dense LDL particles. When triglycerides are high, HDL particles become smaller and are rapidly cleared by the kidneys. The LDL-HDL ratio and triglyceride-to-HDL ratio capture this relationship better than HDL alone. High triglycerides with low HDL flags a pattern of small particle disease and higher ApoB particle count, even if LDL cholesterol looks normal.
Obesity and weight gain. Excess adiposity, particularly visceral fat, is associated with low HDL and insulin resistance. Weight loss — even 5–10% of body weight — reliably raises HDL and improves metabolic function.
Genetic factors and rare lipid disorders. Some families carry genetic variants that lower ApoA1 synthesis (familial hypoalphalipoproteinemia), LCAT deficiency, or CETP variants that affect HDL particle size and metabolism. These are rare but important to identify, as they significantly raise cardiovascular risk independent of other markers.
Aerobic training and cardiovascular fitness. Regular aerobic exercise — running, cycling, swimming, or high-intensity interval training — reliably raises HDL by 5–15% within 8–12 weeks. The effect is dose-dependent: more exercise yields higher HDL. This is one of the most robust interventions and works independently of weight loss, though combining exercise with weight loss amplifies the effect.
Strength training and metabolic conditioning. Resistance training improves insulin sensitivity and metabolic health, indirectly supporting HDL. Combined with aerobic training, it creates broader metabolic benefits than aerobic work alone.
Weight loss and body composition optimization. Reducing total body weight, particularly visceral fat, improves insulin sensitivity and raises HDL. Even modest weight loss (5–10 kg in an overweight individual) produces meaningful HDL increases. The mechanism is improved hepatic lipid metabolism and reduced VLDL production.
Dietary fiber and whole grains. Soluble fiber (oats, legumes, psyllium) and high-fiber whole grains improve HDL and lower triglycerides by altering lipid absorption and hepatic lipogenesis. Refined carbohydrates have the opposite effect. The mechanism involves reduced hepatic cholesterol synthesis and improved gut lipid metabolism.
Alcohol moderation. Moderate alcohol consumption (up to 1 drink daily for women, 1–2 for men) is associated with higher HDL, likely through effects on ApoA1 synthesis and HDL particle clearance. However, this effect is modest and not a primary intervention, as heavy drinking causes far greater metabolic harm.
Omega-3 fatty acids and triglyceride lowering. Omega-3s (from fatty fish or supplements) lower triglycerides and can modestly improve the triglyceride-to-HDL ratio, indirectly supporting HDL particle function. High-dose omega-3s (1–3 g EPA/DHA daily) show clinical benefit in hypertriglyceridemia.
Reducing refined carbohydrate intake. Diets high in refined sugars and simple carbohydrates suppress HDL and raise triglycerides. Shifting toward complex carbohydrates, whole grains, and nutrient-dense foods improves the lipid profile across multiple markers.
The right combination of these interventions depends on your individual metabolic baseline, genetic factors, and full lipid panel — your Loovi longevity doctor will map out the most effective approach in consultation based on your complete biomarker profile and health goals.
HDL alone is a weak predictor of cardiovascular risk. Low HDL is only concerning if it clusters with other abnormalities — elevated triglycerides, low ApoA1, high ApoB, elevated hs-CRP, or poor glycemic control (HbA1c, fasting glucose). Conversely, high HDL does not confer protection if your ApoB is elevated or if you have systemic inflammation. You need the full context: LDL particle count (ApoB), triglyceride metabolism (triglycerides and the TG-to-HDL ratio), total lipid burden (comparing ApoB to LDL-C), inflammation markers (hs-CRP), and glycemic control (HbA1c, fasting insulin). Only when you see these together can you accurately assess cardiovascular risk and decide on intervention priorities.
This is exactly what Loovi's membership does — testing 120+ biomarkers annually and pairing them with unrushed 1-on-1 longevity doctor consultations, physical performance tests (strength, mobility, VO2 max), and an evolving personalized health plan. Instead of chasing individual markers, you get a complete picture of your cardiovascular health, metabolic fitness, and long-term longevity profile. From just 295 SEK/month, with drop-in blood tests at 80+ clinics across Sweden and results in 3 days.
No. That framing, while intuitive, has been decisively challenged by recent evidence. Mendelian randomization studies (Voight et al. 2012) and CETP inhibitor trials (which raised HDL pharmacologically but didn't reduce heart attacks) show that genetically or pharmacologically raising HDL alone does not prevent cardiovascular events. HDL is useful because it tracks metabolic health — but causally, it's ApoB (total atherogenic particle count) that drives atherosclerotic risk. Think of HDL as a health marker, not a health lever.
This pattern suggests you have good reverse cholesterol transport (HDL function) but a large total burden of atherogenic particles (high ApoB). This is called discordance, and it matters clinically — your ApoB is the dominant risk factor here. High ApoB with high HDL often appears in people who exercise heavily but eat a lipid-rich diet, or who have genetic variants that raise both particle production and HDL. The ApoB is what drives your cardiovascular risk in this scenario.
Yes, significantly. High triglycerides with low HDL is a strong flag for small, dense LDL particles (high particle count despite possibly normal LDL cholesterol) and insulin resistance. The triglyceride-to-HDL ratio (> 2 is concerning) is a better predictor of small particle disease than LDL cholesterol alone. If this pattern appears in your results, measuring ApoB and checking fasting glucose and insulin will clarify your metabolic status and risk level.
Almost always, but the magnitude varies. Aerobic training raises HDL by 5–15% typically, and the effect appears within 8–12 weeks with consistent effort. Weight loss amplifies the effect. Some individuals (those with genetic lipid disorders, or those taking certain medications like beta-blockers) may see more modest changes, but the majority respond well. The more consistent your exercise, the better your HDL response.
Yes — statins, beta-blockers, diuretics, and some other medications can modestly lower HDL. However, stopping a medication you need to manage blood pressure or cholesterol is almost never the right move. The cardiovascular protection from the medication typically outweighs the HDL reduction. This is a conversation to have with your doctor, not a reason for self-directed changes.
The test is the same, but the reference ranges are different due to hormonal influences. Women typically have 10–15% higher HDL than men, and estrogen supports ApoA1 synthesis. Post-menopausal women's HDL often declines. Swedish/European reference ranges are > 1.0 mmol/L for men and > 1.2 mmol/L for women. Loovi's optimal ranges are ≥ 1.3 mmol/L for men and ≥ 1.5 mmol/L for women, reflecting better metabolic health.
Rarely, but yes. Values > 2.5 mmol/L have shown paradoxical associations with increased mortality in some cohorts. This is usually driven by underlying conditions (advanced liver disease, genetic HDL metabolism variants, chronic inflammation) rather than HDL elevation itself being protective. If your HDL exceeds 2.5 mmol/L, it's worth discussing with your doctor to investigate the cause.
HDL typically begins rising within 2–4 weeks of consistent aerobic exercise, with meaningful increases (5–15%) visible by 8–12 weeks. Weight loss also takes 8–12 weeks to show HDL benefits. Dietary changes (increased fiber, reduced refined carbs) show changes within 4–6 weeks. So if you make a serious commitment to exercise and nutrition, you should see HDL improvement within 2–3 months of consistent effort.
High-dose niacin (1–3 g daily) reliably raises HDL by 15–25%, but clinical trials (AIM-HIGH, HPS2-THRIVE) showed that raising HDL pharmacologically with niacin did not reduce cardiovascular events when ApoB was already controlled. Lifestyle approaches (exercise, weight loss, dietary changes) are preferred first-line. If your HDL remains stubbornly low despite excellent lifestyle compliance, niacin might be considered as part of a broader risk reduction strategy, but only in consultation with a cardiovascular specialist.
No. HDL levels are not significantly affected by recent food intake, unlike triglycerides. You can test HDL any time of day. Standard Swedish clinical labs include HDL in routine lipid panels, and there's no special preparation needed — no fasting, no special timing relative to exercise or meals. This makes HDL convenient to monitor regularly.
